Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
15 mai 2023 16h15 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
ImmunityBio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
11 mai 2023 10h04 HE
|
Block & Leviton LLP
BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ImmunityBio, Inc. (NASDAQ: IBRX) for potential securities law violations. Investors who have lost money in their...
Alvotech Investigated For Potential Securities Law Violations by Block & Leviton LLP; Investors Who Have Lost Money Are Encouraged to Contact the Firm
14 avr. 2023 11h22 HE
|
Block & Leviton LLP
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Alvotech (NASDAQ: ALVO) for potential securities law violations. Investors who have lost money in their Alvotech...
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
22 mars 2023 13h22 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
02 mars 2023 07h00 HE
|
Checkpoint Therapeutics, Inc
Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024 FDA indicates that it does not currently plan to hold an advisory committee meeting WALTHAM, Mass., March 02, 2023 (GLOBE...
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
04 janv. 2023 08h00 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...
Y-mAbs Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
26 oct. 2022 14h53 HE
|
Block & Leviton LLP
BOSTON , Oct. 26, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for potential securities law violations. Investors who have lost money in...
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMPE
19 août 2022 10h51 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review
24 mai 2022 08h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 24, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
RVNC INVESTOR NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – RVNC
16 déc. 2021 17h15 HE
|
The Rosen Law Firm PA
WHY: NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...